Qingyuan Huang

Dr. Qingyuan Huang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Science Advances
Verified
Journal Article
Open access
QHQingyuan Huang
Qingyuan Huang
FLFei Li
Fei Li
HHHai Hu
Hai Hu
ZFZhaoyuan Fang
Zhaoyuan Fang
ZGZhendong Gao
Zhendong Gao
KWKwok-Kin Wong
Kwok-Kin Wong
Tuberous sclerosis complex subunit 1 ( TSC1 ) and 2 ( TSC2 ) are frequently mutated in non–small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained unexplored. A CRISPR screening in murine Kras G12D / Trp53 −/− (KP) model identified Tsc1 and Tsc2 as potent regulators of programmed cell death ligand 1 (Pd-l1) expression in vitro and sensitivity to anti–programmed cell death receptor 1 (PD-1) treatment in vivo. TSC1 or TSC2 knockout (KO) promoted the transcriptional and membrane expression of PD-L1 in cell lines. TSC2 -deficient tumors manifested an inflamed microenvironment in patient samples and The Cancer Genome Atlas dataset. In syngeneic murine models, KP- Tsc2 -KO tumors showed notable response to anti–PD-1 antibody treatment, but Tsc2 –wild-type tumors did not. Patients with TSC1 / TSC2 -mutant NSCLC receiving immune checkpoint blockade (ICB) had increased durable clinical benefit and survival. Collectively, TSC1 / TSC2 loss defines a distinct subtype of NSCLC characterized as inflamed tumor microenvironment and superior sensitivity to ICB.

11 May 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
YYYonggang Yuan
Yonggang Yuan
GMGe Ma
Ge Ma
XHXuelei Hu
Xuelei Hu
QHQingyuan Huang
Qingyuan Huang
Background: The evaluation of the eighth edition of ypTNM staging system for patients with esophageal cancer was limited in the setting of neoadjuvant therapy.Methods: A total of 2324 patients with esophageal cancer receiving radio(chemo)therapy prior to surgery from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2013 were eligible for the analysis. Kaplan‐Meier method and Cox proportional hazards models were used to estimate overall survivals.Results: Among patients with preoperative therapy, both the seventh edition TNM grouping and the eighth edition ypTNM grouping could significantly stratify the overall survival (both log‐rank P < .001). There was not significant difference in the C‐index of the seventh edition TNM grouping (0.575; 95%CI, 0.558‐0.593) and the eighth edition ypTNM grouping (0.569; 95%CI, 0.551‐0.587) (P = .098). In multivariable Cox analysis, ypN category was the strongest predictor of overall survival (P < .001), followed by tumor grade (HR, 1.33; 95%CI, 1.12‐1.56; P = .001). The combination of ypT, ypN, and ypG categories yielded significantly higher C‐index (0.591; 95%CI, 0.573‐0.609) than that of the seventh edition TNM staging (P = .024).Conclusion: Tumor grade remained an independent predictor of overall survival in the setting of neoadjuvant therapy, and could improve the performance of ypTNM staging system.

27 January 2014 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
JOJ. Ouyang
J. Ouyang
XGX. Gou
X. Gou
YMYu Ma
Yu Ma
QHQingyuan Huang
Qingyuan Huang
TJT. Jiang
T. Jiang

1 December 2023 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
QHQingyuan Huang
Qingyuan Huang
HCHang Cao
Hang Cao
QYQianlan Yao
Qianlan Yao
XZXiaoyan Zhou
Xiaoyan Zhou
HLHang Li
Hang Li
HHHong Hu
Hong Hu
Background: NOTCH1 is frequently mutated in non-small cell lung cancer (NSCLC), and also is a poor therapeutic target. It is of clinical importance to investigate the effects of NOTCH1 mutations on anti-tumor immunity and response to immune checkpoint blockade (ICB). Methods: An observational study with targeted sequencing in 963 NSCLC patients at our center were performed (FUSCC cohort). Data of the Cancer Genome Atlas Pan-Lung Cancer study (TCGA cohort) were analyzed, and gene set enrichment analysis (GSEA) was performed. The Samstein et al cohort included 350 patients with advanced NSCLC undergoing genomic profiling with the MSK-IMPACT assay, and receiving at least one dose of ICB therapy. Results: NOTCH1 mutations were more common in smokers and patients with squamous-cell carcinoma (SCC) (all P value < 0.05). For patients who did not receive ICB therapy (TCGA cohort), the overall survival (OS) of NOTCH1-mutant and -WT patients were comparable (log-rank P = 0.72), while for patients who received ICB therapy in the Samstein et al cohort, NOTCH1-mutant patients had significantly superior OS than WT patients (log-rank P = 0.041). On multivariate Cox analysis, the predictive value of NOTCH1 mutations reached marginal statistical significance (HR, 0.42; 95% CI, 0.17– 1.04; P = 0.059). The median of TMB for NOTCH1-mutant tumors was significantly higher than that for NOTCH1-WT tumors, and GSEA revealed that NOTCH1 mutations manifested various defects in the repair of DNA damage. NOTCH1-mutant tumors displayed an inflamed tumor microenvironment (TME), manifesting as increased PD-L1 expression and tumor-infiltrating CD8+ T cells. Conclusion: NOTCH1 mutations define a molecular subtype of NSCLC, which are more common in smokers and patients with SCC, are characterized with higher TMB, inflamed TME, and display improved survival of ICB therapy for NSCLC patients.

22 December 2023 in Frontiers in Science and Engineering
Verified
Journal Article
Open access
PDF file
WHWenhao Hu
Wenhao Hu
LCLong Chen
Long Chen
XSXiang Shi
Xiang Shi
QHQingyuan Huang
Qingyuan Huang
Currently, there is no universally recognized valve disc slight opening identification technology for online verification in safety valves. For spring-loaded safety valves, there is no online verification method available when the mid-range value is unknown. Particularly in the online verification of spring-loaded safety valves, the existing methods generally suffer from the drawback of poor verification accuracy. This paper proposes a novel approach, centered around a computer system, comprising an acoustic emission sensor, a signal amplifier, a valve stem lifting device, and an additional acoustic emission sensor. The signals indicating the slight opening of the safety valve disc are collected by the acoustic emission sensors, and the extracted features of these signals are subsequently analyzed for identification purposes. This method exhibits high accuracy and generalizability, thereby enhancing the accuracy of online verification results for safety valve disc slight opening. The experimental setup complies with the "TSG-ZF001-2006" (Regulations for Safety Technical Supervision of Safety Valves), and the experimental apparatus demonstrates an error rate below 2% compared to the offline calibration bench, outperforming other methods with 5%-10% higher accuracy than safety valve online verification devices. This approach holds significant potential for widespread adoption within the industry, aligning with SCI (Science Citation Index) standards.